Literature DB >> 2580783

Allospecific T cell recognition of HLA-A2 antigens: evidence for group-specific and subgroup-specific epitopes.

L E Wallace, M A Houghton, A B Rickinson, M A Epstein, B A Bradley.   

Abstract

Interleukin 2-dependent alloreactive cytotoxic T cell lines, with activity predominantly directed against the HLA-A2 antigen, have been generated in vitro by stimulating blood mononuclear cells from donors nonimmune to the Epstein-Barr (EB) virus with appropriate numbers of EB virus-transformed B cells from A2-homozygous individuals. Such effector cells were tested against a panel of EB virus-transformed target cell lines all expressing the serologically defined A2 antigen but typed into "common A2" and "variant A2" subgroups on the basis of their recognition by A2-restricted EB virus-specific cytotoxic T cells. "Variant A2" responder cells cocultivated with "common A2"-bearing stimulators gave rise to effector T cell lines which recognized only the "common A2"-bearing subgroup of targets. By contrast, responder cells from A2-negative donors stimulated with "common A2"-bearing cells produced effector T cell lines in which the strong lysis of "common A2"-bearing targets was accompanied by a lower, but still significant, lysis directed against all targets within the "variant A2" subgroup. In both cases, lysis of the target cells was blocked equally well by the anti-A2-specific monoclonal antibody MA2.1 as by the monoclonal antibody W6/32 specific for HLA-A, -B, and -C determinants. This suggests that HLA-A2 molecules possess at least two distinct sets of epitopes capable of inducing alloreactive T cell cytotoxicity: first, epitopes probably associated with T cell-restricting sites, which generate subgroup-specific responses, and second, epitopes shared by all A2 molecules, and perhaps associated with serologically defined sites, which generate "pan A2" group-specific responses.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2580783     DOI: 10.1007/bf00375373

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  29 in total

Review 1.  HLA-A, -B and -C antigens, their serology and cross-reaction.

Authors:  V C Joysey; E Wolf
Journal:  Br Med Bull       Date:  1978-09       Impact factor: 4.291

2.  Epstein-Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen.

Authors:  L E Wallace; A B Rickinson; M Rowe; M A Epstein
Journal:  Nature       Date:  1982-06-03       Impact factor: 49.962

3.  HLA antigen-related restriction of T lymphocyte cytotoxicity to Epstein-Barr virus.

Authors:  I S Misko; D J Moss; J H Pope
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

4.  Selective reactivation of Epstein-Barr virus-specific cytotoxic T cells by stimulation in vitro with allogeneic virus-transformed HLA-homozygous typing cells.

Authors:  M Rowe; A B Rickinson; S R Beer; M A Epstein; B A Bradley
Journal:  Hum Immunol       Date:  1983-03       Impact factor: 2.850

5.  Cloned cytotoxic T lymphocytes.

Authors:  T Kristensen; B Malissen; M Madsen; C Mawas
Journal:  Tissue Antigens       Date:  1981-07

6.  Comparative structural analysis of HLA-A2 antigens distinguishable by cytotoxic T lymphocytes: variants M7 and DR1.

Authors:  M S Krangel; S Taketani; W E Biddison; D M Strong; J L Strominger
Journal:  Biochemistry       Date:  1982-11-23       Impact factor: 3.162

7.  Virus-immune cytotoxic T cells recognize structural differences between serologically indistinguishable HLA-A2 molecules.

Authors:  W E Biddison; M S Krangel; J L Strominger; F E Ward; G M Shearer; S Shaw
Journal:  Hum Immunol       Date:  1980-10       Impact factor: 2.850

8.  Monoclonal antibodies to Epstein-Barr virus-induced, transformation-associated cell surface antigens: binding patterns and effect upon virus-specific T-cell cytotoxicity.

Authors:  M Rowe; J E Hildreth; A B Rickinson; M A Epstein
Journal:  Int J Cancer       Date:  1982-04-15       Impact factor: 7.396

9.  Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. I. Specificity and HLA restriction of effector cells reactivated in vitro.

Authors:  D J Moss; L E Wallace; A B Rickinson; M A Epstein
Journal:  Eur J Immunol       Date:  1981-09       Impact factor: 5.532

10.  Epitopes on H-2Dd somatic cell mutants recognized by cytotoxic T cells.

Authors:  T A Potter; M A Palladino; D B Wilson; T V Rajan
Journal:  J Exp Med       Date:  1983-10-01       Impact factor: 14.307

View more
  6 in total

1.  Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell recognition in B-cell lines infected with transforming (B95.8) or nontransforming (P3HR1) virus strains.

Authors:  R J Murray; L S Young; A Calender; C D Gregory; M Rowe; G M Lenoir; A B Rickinson
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

2.  HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment.

Authors:  Joseph Rimando; Michael Slade; John F DiPersio; Peter Westervelt; Feng Gao; Chang Liu; Rizwan Romee
Journal:  Blood Adv       Date:  2018-12-26

3.  DNA sequences of the genes that encode the CTL-defined HLA-A2 variants M7 and DK1.

Authors:  D H Mattson; D E Handy; D A Bradley; J E Coligan; E P Cowan; W E Biddison
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

4.  New HLA-A2 variants defined by monoclonal antibodies and cytotoxic T lymphocytes.

Authors:  L J Kennedy; L E Wallace; J A Madrigal; A B Rickinson; J G Bodmer
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

5.  HLAMatchmaker-defined triplet matching is not associated with better survival rates of patients with class I HLA allele mismatched hematopoietic cell transplants from unrelated donors.

Authors:  Rene Duquesnoy; Stephen Spellman; Michael Haagenson; Tao Wang; Mary M Horowitz; Machteld Oudshoorn
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742

6.  Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.

Authors:  R J Murray; M G Kurilla; J M Brooks; W A Thomas; M Rowe; E Kieff; A B Rickinson
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.